Cargando…

Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high grade urothelial carcinoma of the bladder

Immunotherapeutic strategies are increasingly used in the treatment of a number of malignancies including high grade urothelial carcinoma (HGUC) of the bladder. Because of this, detailed and accurate assessment of the tumour immune microenvironment is paramount. In this study, we aimed to correlate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hodgson, Anjelica, Jungbluth, Achim A., Katabi, Nora, Xu, Bin, Downes, Michelle R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596305/ https://www.ncbi.nlm.nih.gov/pubmed/31485721 http://dx.doi.org/10.1007/s00428-019-02661-2

Ejemplares similares

Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
por: Albertsmeier, Markus, et al.
Publicado: (2020)

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
por: Xu, Yichi, et al.
Publicado: (2020)

Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
por: Naik, Adviti, et al.
Publicado: (2021)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas
por: Nettersheim, Daniel, et al.
Publicado: (2016)

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2(Prame) complex
por: Zhang, Wenjuan, et al.
Publicado: (2021)

Upregulation of IFNɣ-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma
por: Olkhov-Mitsel, Ekaterina, et al.
Publicado: (2022)

CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage
por: Al-Maghrabi, Jaudah
Publicado: (2023)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications
por: Balafoutas, Dimitrios, et al.
Publicado: (2013)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study
por: Cazzato, Gerardo, et al.
Publicado: (2022)

Sensitive Immunofluorescent Detection of the PRAME Antigen Using a Practical Antibody Conjugation Approach
por: Sapozhnikova, Ksenia A., et al.
Publicado: (2021)

CD10 expression in urothelial carcinoma of the bladder
por: Bahadir, Burak, et al.
Publicado: (2009)

Cancer-testis antigen expression and immunogenicity in AL amyloidosis
por: Rosenzweig, M A, et al.
Publicado: (2012)

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)
por: Pankov, Dmitry, et al.
Publicado: (2017)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas
por: Bui, Chau M., et al.
Publicado: (2021)

PRAME expression is similar in scar and desmoplastic melanoma
por: Plotzke, Jaclyn M., et al.
Publicado: (2022)

PRAME induces genomic instability in uveal melanoma
por: Kurtenbach, Stefan, et al.
Publicado: (2023)

Prediction of high-grade ureteral urothelial carcinoma on CT urography
por: Sung Tae, Hwang, et al.
Publicado: (2017)

Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer
por: Bowden, Michaela, et al.
Publicado: (2020)

Grading Systems for Canine Urothelial Carcinoma of the Bladder: A Comparative Overview
por: Brambilla, Eleonora, et al.
Publicado: (2022)

The Human EKC/KEOPS Complex Is Recruited to Cullin2 Ubiquitin Ligases by the Human Tumour Antigen PRAME
por: Costessi, Adalberto, et al.
Publicado: (2012)

Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
por: Takata, Katsuyoshi, et al.
Publicado: (2022)

Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients
por: Kulkarni, Nagaraj V., et al.
Publicado: (2022)

Expression of Testis-Specific Gene Antigen 10 (TSGA10) is Associated with Apoptosis and Cell Migration in Bladder Cancer Cells and Tumor Stage and Overall Survival in Patients with Bladder Cancer
por: Wu, Dashan, et al.
Publicado: (2019)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock
por: Muto, Yusuke, et al.
Publicado: (2020)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples
por: Ronchi, Andrea, et al.
Publicado: (2022)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
por: Glutsch, Valerie, et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

Genetic mechanism for the loss of PRAME in B cell lymphomas
por: Mraz, Marek
Publicado: (2022)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

PRAME Expression in Mucosal Melanoma of the Head and Neck Region
por: Ricci, Costantino, et al.
Publicado: (2023)

Molecular and clinicopathological implications of PRAME expression in adult glioma
por: Le, Minh-Khang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f6nc56pp8h67fa7gag0rv1udbm